Monograph Details
|
|
Hematology
> Bleeding disorders
|
|
NEUMEGA |
| Manufacturer |
|
Wyeth Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Thrombopoietic growth factor (Interleukin-11). |
| Generic Name |
|
Oprelvekin 5mg/vial; lyophilized pwd for SC inj after reconstitution; preservative-free. |
| Indications |
|
Prevention of severe thrombocytopenia. To reduce platelet transfusions following myelosuppressive chemotherapy in adults with non-myeloid malignancies who are at high risk of severe thrombocytopenia. |
| Children |
|
Not recommended. |
| Adults |
|
Initiate 6–24hrs after chemotherapy completion. Give by SC inj into abdomen, thigh, or hip; also upper arm if not self-injecting. 50micrograms/kg once daily until post-nadir platelet count is ≥50,000/microliter; max 21 days. Discontinue ≥2days prior to next chemotherapy cycle. Severe renal impairment: CrCl <30mL/min: 25micrograms/kg. May give for ≤6 cycles following chemotherapy. |
| Precautions |
|
Not for use after myeloablative chemotherapy. Monitor fluid balance and electrolytes; increased risk of serious fluid retention with CHF, renal impairment, chronic diuretic or aggressive hydration therapy. Consider draining pre-existing fluid collections (eg, pericardial effusion, ascites). Obtain CBCs before and during therapy; monitor platelet counts. Pre-existing papilledema or tumors involving the CNS. History of stroke, transient ischemic attack, or atrial arrhythmias. Effectiveness unknown with chemotherapy regimens >5 days duration or with regimens associated with delayed myelosuppression (eg. nitrosoureas, mitomycin-C). Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Edema, dyspnea, tachycardia, conjunctival injection, palpitations, atrial arrhythmias, pleural effusions, neutropenic fever, syncope, atrial fibrillation, fever, pneumonia, CHF, pulmonary edema, dilutional anemia, blurred vision, paresthesia, dehydration, skin discoloration, exfoliative dermatitis, eye hemorrhage, stroke, papilledema, hypersensitivity reactions (permanently discontinue if occur). |
| How Supplied |
|
Single-use vials—7 (w. diluent) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
